4T-MMDA-2
4T-MMDA-2, also known as 3,4-methyleneoxythio-6-methoxyamphetamine or as 2-methoxy-4,5-methylenethiooxyamphetamine, is a psychoactive drug of the phenethylamine and amphetamine families related to 3,4-methylenedioxyamphetamine. It is the analogue of MMDA-2 in which one of the oxygen atoms of the methylenedioxy ring, specifically the 4-position oxygen, has been replaced with a sulfur atom.
According to Alexander Shulgin in his 1991 book PiHKAL, a 4T-MMDA-2 dose of 25mg orally might be a threshold dose and the active dose is listed as greater than 25mg. The effects at this "inactive" dose included possible mild exhiliration and a hint of tremor and teeth clenching 3hours after administration. Higher doses were not explored and the duration is unknown. For comparison, MMDA-2 has a dose of 25 to 50mg and a duration of 8 to 12hours.
The effects of 4T-MMDA-2 and various analogues on serotonin and dopamine release in rat brain synaptosomes in vitro were studied by Dennis McKenna and Shulgin and colleagues. 4T-MMDA-2 and MMDA-2 showed essentially abolished monoamine release, in contrast to other related drugs like MDA, MDMA, and MMDA, suggesting that 4T-MMDA-2 would not have entactogenic or stimulant effects. The chemical synthesis of 4T-MMDA-2 has been described.
4T-MMDA-2 was first described in the scientific literature by Alexander Shulgin and colleagues in PiHKAL and in a journal article by 1991. It was first tested by Shulgin in 1977.